PI3K/AKT/mTOR signaling in cancer
PI3K/AKT/mTOR signaling in cancer is a research topic within Molecular Biology. Science Explorer counts 24k research works in it since 1952. 23.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the mTOR signaling pathway, particularly its role in growth control, metabolism, and disease, with a specific emphasis on cancer. The PI3K/AKT pathway, Raptor, TSC2, and rapamycin are central to the research discussed in these papers.
- mTOR
- signaling
- PI3K/AKT pathway
- cancer
- growth control
- metabolism
- Raptor
- TSC2
- rapamycin
- cell growth
- Research works
- 24k fractional, since 1952
- In the world top 10%
- 5.7k per year above
- Top-10% rate
- 23.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -16% the tick is no change
Which countries lead PI3K/AKT/mTOR signaling in cancer research?
By volume, China and the United States publish the most (859 and 746 works in 2022–2025).
By volume, 2022–2025
- 1 China 859 works
- 2 United States 746 works
- 3 India 149 works
- 4 Japan 132 works
- 5 Italy 100 works
- 6 Germany 99 works
- 7 United Kingdom 83 works
- 8 South Korea 76 works
- 9 France 69 works
- 10 Canada 57 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead PI3K/AKT/mTOR signaling in cancer research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most PI3K/AKT/mTOR signaling in cancer research, followed by University of North Carolina at Chapel Hill and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 16 works
- 2 University of North Carolina at Chapel HillUnited States 15 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 15 works
- 4 Memorial Sloan Kettering Cancer CenterUnited States 12 works
- 5 Harvard UniversityUnited States 12 works
- 6 University of MichiganUnited States 11 works
- 7 King Saud UniversitySaudi Arabia 11 works
- 8 Sun Yat-sen UniversityChina 11 works
- 9 Zhejiang UniversityChina 10 works
- 10 Dana-Farber Cancer InstituteUnited States 10 works
Who are the leading researchers in PI3K/AKT/mTOR signaling in cancer?
The most-cited researchers publishing on PI3K/AKT/mTOR signaling in cancer include Gordon B. Mills and Jordi Bruix.
- 1 Gordon B. Mills United States 3.7k citations
- 2 Jordi Bruix Spain 3.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is PI3K/AKT/mTOR signaling in cancer research done?
The largest centres of PI3K/AKT/mTOR signaling in cancer research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Houston.
Largest cities, 2022–2025
Where it is the local speciality
- HoustonUS · 28.1 works3.8×
Location quotient: how much more of its research is in PI3K/AKT/mTOR signaling in cancer than the world average.
Where is the best place to study PI3K/AKT/mTOR signaling in cancer?
Among universities, judged by research, China Pharmaceutical University, Harvard University and King Saud University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | China Pharmaceutical UniversityChina | 59.4 | 26.1% | 12.7× | 8 | +143.3% |
| 2 | Harvard UniversityUnited States | 51.2 | 34.7% | 3.1× | 12 | -46.7% |
| 3 | King Saud UniversitySaudi Arabia | 50.5 | 25.4% | 3.9× | 11 | — |
| 4 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 44.8 | 17.2% | 5.1× | 15 | +31.4% |
| 5 | Wenzhou Medical UniversityChina | 42.4 | 13.4% | 8.6× | 9 | +127.4% |
| 6 | Sichuan UniversityChina | 41.9 | 35.3% | 1.9× | 10 | +0.7% |
| 7 | Cornell UniversityUnited States | 41.8 | 34.4% | 2.8× | 8 | +9.2% |
| 8 | Sun Yat-sen UniversityChina | 32.8 | 23.7% | 2.2× | 11 | +1.3% |
| 9 | Central South UniversityChina | 32.6 | 23.7% | 1.9× | 9 | +63.6% |
| 10 | Zhejiang UniversityChina | 31.7 | 25.6% | 1.7× | 10 | -12.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is PI3K/AKT/mTOR signaling in cancer research growing?
Output in 2018–2022 was 16% lower than in 2013–2017, peaking in 2015. The fastest-growing topics are PI3K/AKT/mTOR signaling in cancer.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.